• 30
Reading Time: 6 minutes

Many diabetic foot ulcers fail to heal despite good standard care: debridement, offloading, infection control and attention to blood flow. Low oxygen levels in the wound bed are one of the reasons. Oxygen is needed for collagen formation, new blood vessel growth and the bacteria-killing activity of white blood cells, and chronic diabetic wounds are often short of it. Topical oxygen therapy (TOT) delivers oxygen directly to the surface of the wound instead of through the whole body, as hyperbaric oxygen does. Over the past decade, randomized trials and several meta-analyses have tested whether this approach actually improves healing.

What Topical Oxygen Therapy Is

Topical oxygen therapy covers several devices that bring oxygen to the open wound. Some enclose the foot and lower leg in a chamber and deliver pressurized oxygen in cycles. Others feed a low, continuous flow of oxygen under the dressing through a small portable unit. Some dressings release oxygen chemically. Unlike hyperbaric oxygen therapy, TOT does not raise oxygen levels in the blood. It works only at the wound surface, and it can usually be used at home.

The TWO2 Randomized Controlled Trial

The strongest single study is the TWO2 trial, published by Frykberg and colleagues in Diabetes Care in 2020. This multinational, double-blinded, sham-controlled trial was run at 17 centres in the United States and Europe. It enrolled patients with chronic diabetic foot ulcers that had shrunk by less than 30% during a two-week run-in period of standard care. Seventy-three patients were randomized. One group received cyclical pressurized topical oxygen at home for 90 minutes a day, five days a week. The other group used an identical-looking device that delivered room air. Both groups also received standard care, including offloading.

At 12 weeks, 41.7% of ulcers in the oxygen group had fully closed, compared with 13.5% in the sham group. After adjusting for ulcer grade, the odds of closure were six times higher with oxygen. At 12 months, 56% of ulcers in the active group were closed versus 27% in the sham group. Serious adverse events were the same in both groups (10 each), and no device-related adverse events were reported. Amputation rates were low in both groups and did not differ significantly.

The trial also had limitations. It was stopped early at its first planned interim analysis because the primary endpoint had been met. Trials stopped early can overestimate treatment effects. The trial was industry-funded, the sample was small, and it was not large enough to show any effect on amputation or quality of life.

What the Meta-Analyses Show

Several systematic reviews have pooled the randomized evidence. Thanigaimani, Singh and Golledge (Diabetic Medicine, 2021) analysed six randomized trials with 530 participants. Complete healing was about twice as likely with topical oxygen (relative risk 1.94), and about five patients needed treatment for one additional ulcer to heal. When only the three trials at low risk of bias were included, the relative risk was 2.37. There were too few amputation data to pool.

An updated review by Sun and colleagues (International Wound Journal, 2022) included seven randomized trials and 614 patients and found a relative risk of complete healing of 1.63. Adverse events were not increased. The authors could not say whether healing time was shortened, and they found signs of possible publication bias. Carter and colleagues (Advances in Wound Care, 2023) limited their analysis to four trials in Wagner grade 1 and 2 ulcers and reported a relative risk of 1.59. They rated the overall evidence as moderate and concluded that the data support TOT for chronic ulcers without infection or ischemia. Several of the authors disclosed financial ties to topical oxygen manufacturers.

Where Topical Oxygen Fits in Current Guidelines

The International Working Group on the Diabetic Foot (IWGDF) 2023 guideline on interventions to improve healing, by Chen and colleagues, reviewed three double-blinded trials and seven non-blinded studies. Of the two low-risk double-blinded trials, one showed a significant benefit for complete healing at 12 weeks and the other showed no difference. The guideline recommends considering topical oxygen as an adjunct to standard care for diabetes-related foot ulcers when standard care alone has failed and the resources exist to support it. This is a conditional recommendation based on low-certainty evidence. The guideline noted that no benefit for amputation was shown, that adverse effects were poorly reported, and that device costs and equity of access are real concerns.

The guideline is also clear that topical oxygen does not replace the basics. Pressure offloading, treatment of infection, revascularization when blood flow is poor, and regular debridement remain the foundation of ulcer care. The trials studied topical oxygen as an addition to these measures, and mostly in ulcers without significant ischemia or active infection.

Clinical Summary

Randomized trials and meta-analyses consistently show that topical oxygen therapy increases complete healing of hard-to-heal diabetic foot ulcers by roughly 1.6 to 2 times when added to good standard care, without an apparent increase in adverse events. The evidence is limited by small trials, industry funding, different device types, short follow-up and possible publication bias, and no benefit for amputation has been shown. Current IWGDF guidance therefore supports topical oxygen as a conditional add-on option for ulcers that have not responded to standard care, not as a first-line or standalone treatment.

References

  1. Frykberg RG, Franks PJ, Edmonds M, et al. A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers: the TWO2 study. Diabetes Care. 2020;43(3):616–624.
  2. Thanigaimani S, Singh T, Golledge J. Topical oxygen therapy for diabetes-related foot ulcers: a systematic review and meta-analysis. Diabetic Medicine. 2021;38(8):e14585.
  3. Sun XK, Li R, Yang XL, Yuan L. Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: an updated systematic review and meta-analysis. International Wound Journal. 2022;19(8):2200–2209.
  4. Carter MJ, Frykberg RG, Oropallo A, et al. Efficacy of topical wound oxygen therapy in healing chronic diabetic foot ulcers: systematic review and meta-analysis. Advances in Wound Care. 2023;12(4):177–186.
  5. Chen P, Campillo Vilorio N, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.